Chemistry: natural resins or derivatives; peptides or proteins; – Peptides of 3 to 100 amino acid residues – 8 to 10 amino acid residues in defined sequence
Reexamination Certificate
2006-08-01
2006-08-01
Helms, Larry R. (Department: 1642)
Chemistry: natural resins or derivatives; peptides or proteins;
Peptides of 3 to 100 amino acid residues
8 to 10 amino acid residues in defined sequence
C514S002600, C424S184100
Reexamination Certificate
active
07084249
ABSTRACT:
The present invention relates to tumor associated antigen (TAA) peptides and to use of same, of polynucleotides encoding same and of cells presenting same as anti-tumor vaccines. More particularly, the present invention relates to tumor associated antigen peptides derived from Uroplakin Ia, Ib, II and III, Prostate specific antigen (PSA), Prostate acid phosphatase (PAP) and Prostate specific membrane antigen (PSMA), BA-46 (Lactadherin), Mucin (MUC-1), and Teratocarcinoma-derived growth factor (CRIPTO-1) and the use of same as anti-tumor vaccines to prevent or cure bladder, prostate, breast or other cancers, carcinomas in particular. Most particularly, the present invention relates to tumor associated antigen peptides which are presentable to the immune system by HLA-A2 molecules.
REFERENCES:
patent: 5455031 (1995-10-01), Ceriani et al.
patent: 5840839 (1998-11-01), Wang et al.
patent: 19516673 (1996-10-01), None
patent: 19758400 (1999-07-01), None
patent: 94 20127 (1994-09-01), None
patent: 95 04548 (1995-02-01), None
patent: WO95/15171 (1995-06-01), None
patent: 95 19783 (1995-07-01), None
patent: 97 08318 (1997-03-01), None
patent: 97 11715 (1997-04-01), None
patent: 97 35021 (1997-09-01), None
patent: 98 43084 (1998-10-01), None
Stubbs et al, 1990, Proc. Natl. Acad. Sci. USA 87;8417-8421.
Sherman, LA et al, 1998 Critical reviews in Immunol, 18(1-2): 47-54.
Ezzell (J. NIH Res, 1995, 7:46-49).
Spitler (Cancer Biotherapy, 1995, 10: 1-3).
Boon (Adv Can Res, 1992, 58:177-210).
Gura (Science, 1997, 278:1041-1042).
Jain (Sci. Am., 1994, 271:58-65).
Curti (Crit. Rev. in Oncology/Hematology, 1993, 14:29-39.
Hartwell et al (Science, 1997, 278:1064-1068).
Larocca et el (1991, Cancer Res. 51; 4994-4998).
Riott et al (Immunology, Fourth Edition, 1996, Mosby, p. 7.9 col. 1 lines 1-10).
McMurry, J (1988, Organic Chemistry, p. 65 only).
Belllone et al, (Sep. 1, 2000, J Immunol., vol. 165, p. 2651-6).
Guagler et al., (1994, J. Exp. Med. vol. 179, pp. 921-930).
Nseyo et al., Immunotherapy of Bladder Cancer, Seminars in Surgical Oncology, 13:342-349 (1997).
Urban et al., Tumor Antigens, Annu. Rev. Immunol., 10:617-44 (1992).
Acres et al., Vaccinia Virus MUC1 Immunization of Mice: Immune Response and Protection Against the Growth of Murine Tumors Bearing the MUC1 Antigen, Journal of Immunotherapy, 14:136-143 (1993).
Gjertsen et al., Ex vivo ras Peptide Vaccination in Patients with Advanced Pancreatic Cancer: Results of A Phase I/II Study, Int. J. Cancer, 65:450-453 (1996).
Murphy et al., Phase I Clinical Trial: T-Cell Therapy for Prostate Cancer Using Autologus Dendritic Cells Pulsed With HLA-A0201-Specific Peptides from Prostate-Specific Membrane Antigen, The Prostate, 29:371-380 (1996).
Xue et al., Induction of Human Cytotoxic T Lymphocytes Specific for Prostate-Specific Antigen, The Prostate, 30:73-78 (1997).
Correale et al., In Vitro Generation of Human Cytotoxic T Lymphocytes Specific for Peptides Derived From Prostate-Specific Antigen, Journal of the National Cancer Institute, 89(4)293-300 (1997).
Tjoa et al., Presentation of Prostate Tumor Antigens by Dendritic Cells Stimulates T-Cell Proliferation and Cytotoxicity, The Prostate, 28:65-69 (1996).
Barnd et al., Specific, Major Histocompatibility Complex-Unrestricted Recognition of Tumor-Associated Mucins by Human Cytotoxic T Cells, Proc. Natl. Acad. Sci. USA, 86:7159-7163 (1989).
Agrawal et al., In Vitro Induction of MUC-1 Peptide-Specific Type 1 T Lymphocyte and Cytotoxic T Lymphocyte Responses from Healthy Multiparous Donors, The Journal of Immunology, 157:2089-2095 (1996).
Couto et a., Anti-BA46 Monoclonal Antibody Mc3: Humanization Using A Novel Positional Consensus and In Vivo and In Vitro Characterization, Cancer Research, 55:1717-1722 (1995).
Domenech et al., In Vito Studies of MHC-Restricted Recognition of A Peptide From the MUC1 Tandem Repeat Domain by CTL, FASEB J., 9:A1023.
Apostolopoulos et al., Induction of HLA-A2-Restricted CTLs to the Mucin 1 Human Breast Cancer Antigen, The Journal of Immunology, 159:5211-5218 (1997).
Peshwa et al., Induction of prostate tumor-specific CD8+cytotoxic T-lymphocytes in vitro using antigen-presenting cells pulsed with prostatic acid phosphatase peptide,The Prostate, 36:129-138 (1998).
Salgaller et al., Report of immune monitoring of prostate cancer patients undergoing T-cell therapy using dendritic cells pulsed with HLA-A2-Specific peptides from prostate-specific membrane antigen (PSMA),The Prostate, 35:144-151 (1998).
Weinstein B: “Chemistry and Biochemistry of Amino Acids, Peptides and Proteins, Passage” Chemistry and Biochemistry of Amino Acids, Peptides, and Proteins, XXXX, vol. 7, p. 266-357 XP002032461.
Bar-Haim Erez
Carmon Lior
Eisenbach Lea
Fitzer-Attas Cheryl
Fridkin Matityahu
Browdy and Neimark PLLC
Helms Larry R.
Yeda Research and Development Co. Ltd.
Yu Misook
LandOfFree
Tumor associated antigen peptides and use of same as... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Tumor associated antigen peptides and use of same as..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Tumor associated antigen peptides and use of same as... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3685890